Recently, GlaxoSmithKline (GSK), a British multinational pharmaceutical and biotechnology company, made public its decision to withdraw from Nigeria, ending its 51-year presence in the country.
They have joined the list of multinational companies that have exited the country.
The GSK UK Group communicated its strategic intention to discontinue the marketing and sales of prescription medicines and vaccines in Nigeria through GSK’s local operating companies.
Instead, they plan to shift to a third-party direct distribution model for their pharmaceutical products in the region.
We’ll explore how the pharmaceutical and biotechnology company started in Nigeria, what it offered, and the implications of its exit.
Are you ready? Let’s go!
GlaxoSmithKline in Nigeria
GlaxoSmithKline Consumer Nigeria Plc started in Nigeria on July 1, 1972, after being incorporated as Beecham Limited on June 23, 1971.
GSK got listed on the Nigerian Stock Exchange in 1977, reflecting its commitment to the Nigerian market and enabling public investment in its endeavors.
Subsequently, recognizing the potential for further growth and expansion, the company took a strategic step by establishing an advanced drinks factory at Agbara Industrial Estate, Ogun State, in 1982.
This ultra-modern facility served as a platform to not only enhance its existing operations but also facilitate the production of Oral Healthcare (OHC) and Wellness products.
Over time, the Agbara plant underwent expansions and upgrades, reflecting GlaxoSmithKline’s dedication to providing quality healthcare and wellness solutions to the Nigerian populace.
GSK’s mission centered around the idea of helping people “do more, feel better, and live longer.”
The company’s mission was to enhance global health by creating innovative and excellent pharmaceuticals and healthcare solutions to tackle critical health issues in Nigeria.
GSK prioritized ethical conduct, transparency, and social responsibility as fundamental principles that drive its business practices.
What is the Product of GlaxoSmithKline Nigeria?
In Nigeria, GlaxoSmithKline (GSK) offered a variety of products, such as specialty medicines, vaccines, and general medicines.
These products targeted various health conditions and medical requirements, contributing to better healthcare in the country.
Here are the main segments of GSK’s product portfolio in Nigeria:
1. Specialty Medicines
GSK’s experts are dedicated to finding innovative treatments for the human body, with a focus on specialty medicines that form a valuable pipeline of new products.
They develop medicines for a wide range of illnesses and medical conditions.
The specialty division specifically concentrates on creating and promoting prescription medicines to address various diseases and medical needs.
GSK offered a variety of medicines in Nigeria:
- Antiviral drugs: For HIV/AIDS and hepatitis treatment.
- Antibiotics: To manage bacterial infections.
- Respiratory medications: For asthma and COPD.
- Cardiovascular drugs: To address heart conditions.
- Oncology treatments: For various cancers.
2. Vaccines
GSK focuses on combating infectious diseases at all life stages.
They make use of advanced technologies, including adjuvants and mRNA, and collaborate with partners to develop highly effective vaccines that stay ahead of diseases worldwide.
These vaccines are essential for public health initiatives.
Some of the key vaccines made available to Nigerians are listed below:
- Childhood vaccines: Guarding against measles, polio, diphtheria, tetanus, pertussis, and more.
- Travel vaccines: Protect travelers from specific diseases in different regions.
- Flu vaccines: Reducing the impact of seasonal influenza outbreaks.
- Meningococcal vaccines: Safeguarding against meningitis in certain areas of Nigeria.
3. General Medicines
GSK provided various over-the-counter healthcare products for people’s well-being.
These medicines were recommended by general healthcare practitioners in primary care or community settings.
These products are as follows:
- Pain relief medications: Over-the-counter pain relievers for headaches, muscle pain, and more.
- Oral health products: Toothpaste, mouthwash, and dental care items.
- Nutritional supplements: Vitamins, minerals, and dietary supplements.
- Digestive health products: Antacids, probiotics, and digestive aids.
- Skincare and personal care products: Lotions, creams, and other self-care items.
READ ALSO:
- How to Crack Your Modem to a Universal Modem
- Usaka: A Place in Nigeria where the gods Forbid Afternoon Sex
Contributions of GlaxoSmithKline to Healthcare in Nigeria
Throughout its tenure, GlaxoSmithKline played an essential role in the country’s healthcare sector.
The question is, “What are those roles?”
1. Access to Medicines and Vaccines
GSK provided medicines and vaccines in Nigeria.
They made sure life-saving drugs, antivirals, antibiotics, and vaccines were available to fight infectious diseases and reduce illness in the country.
2. Disease Prevention and Immunization
GSK offered vaccines that prevented diseases in Nigeria.
Childhood vaccines like measles and polio are vital for protecting young children from preventable illnesses.
GSK’s meningococcal vaccines also helped address meningitis, a serious health issue in some parts of Nigeria.
3. Research and Development (R&D)
GSK’s dedication to research and development led to medical advancements and innovative healthcare solutions.
They invested in R&D to create better medicines and vaccines, benefiting healthcare in Nigeria and globally.
4. Healthcare Infrastructure Support
The company engaged in initiatives that support and strengthened healthcare infrastructure in Nigeria.
GSK collaborated with local healthcare providers, government agencies, and non-governmental organizations to improve healthcare facilities and provide medical education.
5. Disease Awareness and Education
GSK took part in campaigns to raise awareness about diseases and educate the public.
These efforts encouraged people to learn about health conditions and preventive measures, empowering them to take care of their well-being.
6. Combating Infectious Diseases
GSK’s antiviral medications and vaccines were instrumental in Nigeria’s efforts to combat infectious diseases like HIV/AIDS, hepatitis, and influenza.
GSK helped control the spread of diseases by offering effective treatments and preventive measures.
7. Corporate Social Responsibility (CSR) Programs
GSK implemented various CSR initiatives that focus on improving healthcare access and promoting community well-being.
These programs often involved collaborations with local partners and NGOs to address specific health needs and provide support to vulnerable populations.
8. Capacity Building and Training
GSK supported capacity building and training programs for healthcare professionals in Nigeria.
This helped enhance medical expertise, ensures the proper use of medications, and strengthens healthcare systems in the country.
Possible Reasons for GlaxoSmithKline’s Exit from Nigeria
The decision of GSK to exit Nigeria likely stems from a combination of factors
1. Declining Financial Performance
GSK might have left Nigeria due to its financial performance decline.
The drop in sales during the first half of the year resulted in lower revenue and profits compared to previous years.
2. Loss of Investor Confidence
Another crucial factor contributing to GSK’s exit could be the loss of investor confidence.
GSK Nigeria’s shares experienced a sharp decline from a peak in 2014.
The decline in share value and market performance may have made investors lose confidence in the company’s future and financial stability.
This probably resulted in less interest in holding shares of GSK in Nigeria.
3. Inability to Compete Effectively
GSK Nigeria might have faced challenges in effectively competing in the dynamic Nigerian market.
The company might have lost its competitive edge over time, struggling to keep up with competitors and new entrants.
This inability to maintain a strong market position and innovate to meet evolving consumer demands could have impacted GSK’s overall growth and expansion in Nigeria.
4. Fuel Subsidy Removal and Exchange Rate Unification
The removal of fuel subsidies and exchange rate unification in Nigeria might have further impacted GSK’s financial performance in the country.
These policy changes could have affected the cost of doing business, import/export dynamics, and currency fluctuations, creating uncertainties and challenges for GlaxoSmithKline.
With the unification of the exchange rate, the Nigerian foreign exchange market became more transparent, exposing instances of over-invoicing and capital flight.
Increased transparency may have impacted the profit-making goals of GSK.
5. Changing Business Environment
Nigeria’s business environment is dynamic and subject to various macroeconomic and policy changes.
GSK may have shifted focus and resources to more promising markets due to challenges and economic changes.
READ ALSO:
- Top 5 World’s Richest Women, Source of Wealth & Their Giving
- Cryptocurrency: Best Coins to Buy and How to Invest
What Does GlaxoSmithKline’s Exit Mean?
GSK’s departure from Nigeria could bring about various challenges in the country’s healthcare and pharmaceutical industries.
The potential challenges could include:
1. Increased Drug Importation
With GSK’s departure, Nigeria may become more dependent on importing pharmaceutical products that were previously manufactured locally by the company.
This could lead to higher costs for these drugs, as importation often involves additional expenses such as shipping, tariffs, and taxes.
Higher drug prices may put a strain on healthcare budgets and affect affordability for patients who rely on these medications.
2. Reduced Availability of Certain Medications
GSK’s product line includes popular and widely used drugs like Panadol, Andrews Liver Salt, Macleans, Ampiclox, and Sensodyne.
The company’s exit may result in a reduced availability of these medications in the Nigerian market, potentially leading to shortages and difficulty accessing essential drugs for patients.
3. Direct Contribution
GSK’s operations in Nigeria likely contributed to the country’s GDP through various channels, including sales revenue, taxes, and employment generation.
With GSK’s exit, the direct contribution of the company to Nigeria’s GDP would cease, resulting in a decline in the value-added by GSK’s activities.
4. Employment and Labor Market
GSK’s departure could lead to job losses for its employees and those in related sectors, such as distribution, sales, and marketing.
The reduction in employment opportunities might impact consumer spending and overall economic activity, potentially leading to a slowdown in the economy.
GlaxoSmithKline’s exit from Nigeria after 51 years leaves a gap in essential medicines and healthcare solutions.
This exit poses challenges for the healthcare sector.
Moving forward, the government and stakeholders should collaborate to maintain access to quality healthcare products, attract investments, and prioritize the well-being of Nigerians.
